NCT01393119 - Phase II, Dose Finding Study of GTx-758 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Prostate Cancer

Interventions

DRUG

GTx-758

3-fluoro-N-( 4-fluorophenyl)-4-hydroxy-N-( 4-hydroxyphenyl) benzamide; a nonsteroidal selective estrogen receptor (ER) a agonist

Trial Locations (21)

12208

GTx Investigative Site, Albany

13210

GTx Investigative Site, Syracuse

13421

GTx Investigative Site, Oneida

19004

GTx Investigative Site, Bala-Cynwyd

21204

GTx Investigative Site, Towson

21401

GTx Investigative Site, Annapolis

28025

GTx Investigative Site, Concord

30076

GTx Investigative Site, Roswell

33180

GTx Investigative Site, Aventura

33607

GTx Investigative Site, Tampa

33710

GTx Investigative Site, St. Petersburg

34205

GTx Investigative Site, Bradenton

43220

GTx Investigative Site, Columbus

45212

GTx Investigative Site, Cincinnati

47130

GTx Investigative Site, Jeffersonville

71106

GTx Investigative Site, Shreveport

85032

GTx Investigative Site, Phoenix

85306

GTx Investigative Site, Glendale

91942

GTx Investigative Site, La Mesa

92404

GTx Investigative Site, San Bernardino

08690

GTx Investigative Site, Hamilton